S

Shandong Weigao Orthopaedic Device Co Ltd
SSE:688161

Watchlist Manager
Shandong Weigao Orthopaedic Device Co Ltd
SSE:688161
Watchlist
Price: 31.55 CNY 4.47% Market Closed
Market Cap: ¥12.6B

Shandong Weigao Orthopaedic Device Co Ltd
Capital Expenditures

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Shandong Weigao Orthopaedic Device Co Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
S
Shandong Weigao Orthopaedic Device Co Ltd
SSE:688161
Capital Expenditures
-¥24.3m
CAGR 3-Years
40%
CAGR 5-Years
3%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Capital Expenditures
-¥285.6m
CAGR 3-Years
-26%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Capital Expenditures
-¥166.9m
CAGR 3-Years
-2%
CAGR 5-Years
9%
CAGR 10-Years
3%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Capital Expenditures
-¥2B
CAGR 3-Years
-2%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Andon Health Co Ltd
SZSE:002432
Capital Expenditures
-¥268.9m
CAGR 3-Years
-10%
CAGR 5-Years
-32%
CAGR 10-Years
-18%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Capital Expenditures
-¥1.9B
CAGR 3-Years
-78%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
No Stocks Found

Shandong Weigao Orthopaedic Device Co Ltd
Glance View

Market Cap
12.6B CNY
Industry
Health Care

Nestled in the bustling economic landscape of China, Shandong Weigao Orthopaedic Device Co Ltd has carved a respected niche for itself in the realm of medical equipment. The company, founded as a subsidiary of the larger Weigao Group, specializes in the design, production, and distribution of orthopedic devices. Its journey starts with an unwavering commitment to incorporating advanced technology into healthcare solutions. Shandong Weigao has honed its focus on spinal, trauma, and joint-related products, ensuring that its offerings meet international standards and cater to both domestic and global markets. Operating within an industry where precision and reliability are paramount, the company has leveraged a well-established network to distribute its products to hospitals, clinics, and healthcare facilities, thus embedding its roots deeply within the healthcare infrastructure. This thriving enterprise makes money by delivering value through its diverse product portfolio tailored to meet the complex and varied needs of orthopedic treatments. Its revenue model is centered around a combination of direct sales, strategic partnerships, and long-term contracts with healthcare providers. By engaging in continuous research and development, Shandong Weigao not only expands its product lines but also enhances existing solutions, ensuring they remain cutting-edge. This emphasis on innovation has enabled the company to maintain a competitive edge in a rapidly evolving market, positioning itself as a leader in China’s orthopedic device industry. Through strategic market penetration and an adept understanding of regulatory landscapes, Shandong Weigao Orthopaedic Device Co Ltd not only sustains its growth but also contributes significantly to the advancements in orthopedic healthcare.

Intrinsic Value
28.25 CNY
Overvaluation 10%
Intrinsic Value
Price ¥31.55
S

See Also

What is Shandong Weigao Orthopaedic Device Co Ltd's Capital Expenditures?
Capital Expenditures
-24.3m CNY

Based on the financial report for Dec 31, 2024, Shandong Weigao Orthopaedic Device Co Ltd's Capital Expenditures amounts to -24.3m CNY.

What is Shandong Weigao Orthopaedic Device Co Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
3%

Over the last year, the Capital Expenditures growth was 43%. The average annual Capital Expenditures growth rates for Shandong Weigao Orthopaedic Device Co Ltd have been 40% over the past three years , 3% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett